WO2002072104A3 - Antihypertensive agent and cholesterol absorption inhibitor combination therapy - Google Patents

Antihypertensive agent and cholesterol absorption inhibitor combination therapy Download PDF

Info

Publication number
WO2002072104A3
WO2002072104A3 PCT/US2002/006570 US0206570W WO02072104A3 WO 2002072104 A3 WO2002072104 A3 WO 2002072104A3 US 0206570 W US0206570 W US 0206570W WO 02072104 A3 WO02072104 A3 WO 02072104A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol absorption
absorption inhibitor
combination therapy
antihypertensive agent
inhibitor combination
Prior art date
Application number
PCT/US2002/006570
Other languages
French (fr)
Other versions
WO2002072104A2 (en
Inventor
Steven A Nichtberger
Original Assignee
Merck & Co Inc
Steven A Nichtberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Steven A Nichtberger filed Critical Merck & Co Inc
Priority to AU2002336267A priority Critical patent/AU2002336267B2/en
Priority to CA002439920A priority patent/CA2439920A1/en
Priority to EP02750567A priority patent/EP1389114A2/en
Priority to JP2002571063A priority patent/JP2004523569A/en
Priority to US10/469,610 priority patent/US20040116510A1/en
Publication of WO2002072104A2 publication Critical patent/WO2002072104A2/en
Publication of WO2002072104A3 publication Critical patent/WO2002072104A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention includes methods for treating atherosclerosis and preventing atherosclerotic disease events in a hypertensive patient comprising administering to the patient a therapeutically or prophylactically effective amount of at least one antihypertensive compound in combination with a therapeutically effective amount of a cholesterol absorption inhibitor. The invention also includes a composition comprising at least one antihypertensive compound and a cholesterol absorption inhibitor in therapeutically effective amounts, and a pharmaceutically acceptable carrier.
PCT/US2002/006570 2001-03-08 2002-03-05 Antihypertensive agent and cholesterol absorption inhibitor combination therapy WO2002072104A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002336267A AU2002336267B2 (en) 2001-03-08 2002-03-05 Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CA002439920A CA2439920A1 (en) 2001-03-08 2002-03-05 Antihypertensive agent and cholesterol absorption inhibitor combination therapy
EP02750567A EP1389114A2 (en) 2001-03-08 2002-03-05 Antihypertensive agent and cholesterol absorption inhibitor combination therapy
JP2002571063A JP2004523569A (en) 2001-03-08 2002-03-05 Combination therapy of antihypertensives and cholesterol absorption inhibitors
US10/469,610 US20040116510A1 (en) 2002-03-05 2002-03-05 Antihypertensive agent and cholesterol absorption inhibitor combination therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27428801P 2001-03-08 2001-03-08
US60/274,288 2001-03-08

Publications (2)

Publication Number Publication Date
WO2002072104A2 WO2002072104A2 (en) 2002-09-19
WO2002072104A3 true WO2002072104A3 (en) 2003-07-24

Family

ID=23047586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006570 WO2002072104A2 (en) 2001-03-08 2002-03-05 Antihypertensive agent and cholesterol absorption inhibitor combination therapy

Country Status (5)

Country Link
EP (1) EP1389114A2 (en)
JP (1) JP2004523569A (en)
AU (1) AU2002336267B2 (en)
CA (1) CA2439920A1 (en)
WO (1) WO2002072104A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374641T1 (en) * 2001-01-26 2007-10-15 Schering Corp COMBINATIONS OF THE PPAR ACTIVATOR FENOFIBRATE WITH THE STEROL ABSORPTION INHIBITOR EZETIMIBE FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS
EP2039357A2 (en) * 2001-01-26 2009-03-25 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
KR20080067717A (en) * 2001-01-26 2008-07-21 쉐링 코포레이션 A pharmaceutical composition for treating vascular conditions, comprising sterol absorption inhibitor(s) and blood modifier(s)
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
ATE485267T1 (en) 2003-12-23 2010-11-15 Astrazeneca Ab DIPHENYLAZETIDINONE DERIVATIVES WITH CHOLESTERINE ABSORPTION INHIBITING EFFECT
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
KR20070063592A (en) * 2005-09-08 2007-06-19 테바 파마슈티컬 인더스트리즈 리미티드 Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
RU2554947C2 (en) * 2009-11-30 2015-07-10 Цзянсу Хансох Фармасьютикал Груп Ко., Лтд. Azylsartane salts with organic amines, method for producing and using them
JP6018420B2 (en) * 2012-06-05 2016-11-02 ニプロ株式会社 Pharmaceutical composition comprising an angiotensin II receptor antagonist and thiazide diuretic

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications

Also Published As

Publication number Publication date
AU2002336267B2 (en) 2006-10-05
EP1389114A2 (en) 2004-02-18
CA2439920A1 (en) 2002-09-19
JP2004523569A (en) 2004-08-05
WO2002072104A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
EE200200086A (en) Use of a renin-angiotensin system inhibitor, a combined product, and a method for preventing cardiovascular events
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2002058696A3 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2001054679A3 (en) Transdermal composition containing an anesthetic and a vasodilator agent
AU4438601A (en) Therapeutic combinations of antihypertensive and antiangiogenic agents
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2368186A1 (en) Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
WO2004062624A3 (en) Method of treating nausea, vomiting, retching or any combination thereof
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2001041754A3 (en) Inhibitors of collagen-induced platelet aggregation
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
WO2004028464A3 (en) Methods and compositions for modification of splicing of pre-mrna
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
WO2001043761A3 (en) Methods for treating and preventing damage to mucosal tissue
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002336267

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2439920

Country of ref document: CA

Ref document number: 10469610

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002750567

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002571063

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002750567

Country of ref document: EP